Literature DB >> 4049474

Determination of warfarin in human plasma by high performance liquid chromatography and photodiode array detector.

P M Ueland, G Kvalheim, P E Lønning, S Kvinnsland.   

Abstract

A simple liquid chromatographic method for the determination of warfarin in human plasma is described. The method involves precipitation of plasma proteins with acetonitril. No further processing of samples is required. The supernatant was analyzed on a short (10 cm) 3-microns reversed-phase column eluted with 23% acetonitril in 100 mM ammonium formate, pH 3.5. The method takes advantage of the fact that warfarin dissolved in this mobile phase has a characteristic absorbance spectrum with distinct peaks at 271, 281, and 305 nm. Using an online photodiode array detector, the UV spectrum could be recorded during analysis without interrupting the flow of the mobile phase. This spectral information improves identification possibilities and evaluation of the purity of the chromatographic peaks. Warfarin was separated from other UV-absorbing compounds in plasma in less than 3 min, and there was no interference from numerous drugs given to patients. The standard curve (305 nm) was linear in the concentration range observed after oral intake of the single dose of warfarin and for a time corresponding to several half-lives. The detection limit of the method was about 0.1 microgram/ml when the absorbance was recorded at 305 nm. At this wavelength, the solvent front was small relative to that observed at lower wavelengths. The precision of the method, given as coefficient of variation, was 6.4%. The method was used for the determination of plasma half-lives of R- and S-warfarin in humans.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4049474     DOI: 10.1097/00007691-198507030-00018

Source DB:  PubMed          Journal:  Ther Drug Monit        ISSN: 0163-4356            Impact factor:   3.681


  4 in total

1.  Ponalrestat does not cause a protein binding interaction with warfarin in diabetic patients.

Authors:  R F Moulds; R O Fullinfaw; R W Bury; W E Plehwe; N Jacka; K M McGrath; F I Martin
Journal:  Br J Clin Pharmacol       Date:  1991-06       Impact factor: 4.335

2.  Aminoglutethimide enzyme induction: pharmacological and endocrinological implications.

Authors:  P E Lønning
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

3.  The influence of a graded dose schedule of aminoglutethimide on the disposition of the optical enantiomers of warfarin in patients with breast cancer.

Authors:  P E Lønning; P M Ueland; S Kvinnsland
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

4.  Effect of oral high-dose progestins on the disposition of antipyrine, digitoxin, and warfarin in patients with advanced breast cancer.

Authors:  S Lundgren; S Kvinnsland; E Utaaker; O Bakke; P M Ueland
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.